Efficacy of Risankizumab on Symptoms in Patients With Scalp Psoriasis in a Post-Hoc Analysis of the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16

Risankizumab demonstrated significant improvements in the overall Psoriasis Symptom Scale and showed greater improvements in each individual symptom component compared with placebo in patients with scalp psoriasis at week 16 These findings support the efficacy of risankizumab in patients with scalp psoriasis